Our Science

Our Science

Posters

Year

Crohn's and Colitis Conference, 2025

February 7, 2025

Development and Characterization of SL-325, a DR3-targeted, Antagonistic Antibody for the Treatment of IBD

SITC, 2024

November 5, 2024

Deciphering the Cellular Signals that Promote Vγ9Vδ2+ T Cell Proliferation and Tumor Cell Killing by a CD33 Antigen Targeted Gamma Delta T-cell Engager in Combination with Zoledronate

SITC, 2024

November 5, 2024

mRNA Delivered TIGIT-Fc-Light Potentiates Anti-Tumor Activity in the Setting PD-1 Acquired Resistance

AACR, 2024

April 10, 2024

A CD33 Antigen Targeted Gamma Delta T-cell Engager in Combination with Zoledronate Promotes Vγ9Vδ2+ T cell Proliferation and Cytotoxicity Against Acute Myeloid Leukemia

ASH, 2023

December 11, 2023

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 as Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome/Neoplasms (HR-MDS) Patients (pts)

ASCO 2023

June 5, 2023

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer

AACR 2023

April 17, 2023

Rapid Serial Killing of Target Cells by Vγ9Vδ2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein

SITC 2022

November 10, 2022

Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity

AACR 2022

April 8, 2022

LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activation

AACR 2022

April 8, 2022

Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killing

SITC 2021

November 12, 2021

Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer (NCT04406623)

SITC 2021

November 12, 2021

Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics that Stimulate Target Cells to Migrate from the Peripheral Blood

SITC 2021

November 12, 2021

LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-Tumor Immunity in the Setting of PD-(L)1 and TIGIT Checkpoint Blockade

SITC 2021

November 12, 2021

Phase 1 dose escalation of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas (NCT03894618)

AACR 2021

August 26, 2021

TNFSF14 (LIGHT) Co-Stimulation in Combination with Dual TIGIT/PD1 Checkpoint Inhibition (CPI) Induces Anti-Tumor Immunity in a CPI Acquired Resistance (AR) Model that Shares Transcriptional Similarities to Lung Cancer Patients Who Acquire Resistance to CPI

AACR 2021

August 26, 2021

Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins

SITC 2019

November 11, 2019

An engineered bi-functional fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells

SITC 2019

November 11, 2019

Co-Stimulation of OX40 or LTβ Reprogams Exhausted Lymphocytes to Acquire an Effector Phenotype in the Setting of Combined TIGIT and Checkpoint Blockade

SITC 2018

January 25, 2019

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-FC-OX40L), For Cancer Immunotherapy

SITC 2018

January 25, 2019

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy

SITC 2018

January 2, 2019

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy